

Please type a plus sign (+) inside this box ☐Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



TRANSMITTAL FORM


(REMARKS) used for all correspondence after initial filing)

		Application Number	10/509,362
		Filing Date	September 23, 2004
		First Named Inventor	BIEDERMANN et al.
		Group/Art Unit	Unassigned
		Examiner Name	Unassigned
Total Number of Pages in This Submission		Attorney Docket Number	25846-0005

ENCLOSURES (check all that apply)


<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request 3 months <input checked="" type="checkbox"/> Information Disclosure Statement and References. <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below): stamped return postcard
Remarks AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT 08-1641 FOR ANY FEES DUE IN CONNECTION WITH THIS PAPER.		

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Firm or Individual name	Sam L. Nguyen, Reg. No. 52,496 HELLER EHRMAN WHITE & McAULIFFE LLP		
Signature			
Date	December 29, 2004	Customer Number:	25213

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: Mail Stop Fee Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Typed or printed name	Sylvia Rogers		
Signature		Date	12/29/04

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PATENT

Attorney Docket No. 25846-0005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application)	
)	Art Unit: Unassigned
Inventors: BIEDERMANN, et al.)	
)	Examiner: Unassigned
Application No.: 10/509,362)	
)	
Filed: September 23, 2004)	
)	
Title: Use of Pyridyl Amides as Inhibitors of)	
Angiogenesis)	
)	

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicants. Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

- ☐ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):
- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --
 - ☐ (2) It is being filed within 3 months of entry of a national stage
-- OR --
 - ☒ (3) It is being filed before the mail date of the first Office Action on the merits
-- OR --
 - ☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

☐ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:

☐ a certification as specified in §1.97(e) is provided below; **or**

☐ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:

A. a certification as specified in §1.97(e) is completed below; and

B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; **and**

C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

☒ **Fee Authorization.** The Commissioner is hereby authorized to charge the above-referenced fee of \$180 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Docket No. 25846-0005).

Respectfully submitted,
HELLER EHRMAN WHITE & MCAULIFFE LLP

Dated: December 29, 2004

By: Sam L. Nguyen
Sam L. Nguyen (Reg. No. 52,496)

275 Middlefield Road
Menlo Park, CA 94025-3506
(650) 324-7000
Customer No. 25213

INFORMATION DISCLOSURE STATEMENT PTO-1449			ATTY. DOCKET NO. 25846-0005		SERIAL NO. 10/509,362		
			APPLICANT BIEDERMANN, et al.				
			FILING DATE September 23, 2004		GROUP: Unassigned		
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
	4,778,796	10/18/88	Uno et al.	514	252	07/11/86	
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 97/48695	12/24/97	PCT			<input type="checkbox"/>	<input checked="" type="checkbox"/>
	WO 99/31063	06/24/99	PCT			<input type="checkbox"/>	<input checked="" type="checkbox"/>
	WO 99/31064	06/24/99	PCT			<input type="checkbox"/>	<input checked="" type="checkbox"/>
	WO 99/31060	06/24/99	PCT			<input type="checkbox"/>	<input checked="" type="checkbox"/>
	WO 98/02170	01/22/98	PCT			<input type="checkbox"/>	<input checked="" type="checkbox"/>
	WO 99/31087	06/24/99	PCT			<input type="checkbox"/>	<input checked="" type="checkbox"/>
	WO 97/48696	12/24/97	PCT			<input type="checkbox"/>	<input checked="" type="checkbox"/>
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
		Y. Nishikawa et al. "Acrylamide Derivatives as Antiallergic Agents. 2. Synthesis and Structure-Activity Relationships of N-[4-[4-(Diphenylmethyl)-1-piperazinyl]butyl]-3-(3-pyridyl)acrylamides", J. Med. Chem. (1989) 32:583-593.					
		Napoleone Ferrara, "Molecular and Biological Properties of Vascular Endothelial Growth Factor", J. Mol. Med (1999) 77:527-543.					
		N. Daotai et al., "Eicosanoid Regulation of Angiogenesis: Role of Endothelial Arachidonate 12-lipoxygenase", Hemostasis, Thrombosis, and Vascular Biology, Blood, 1 April (2000) 95:7.					
		R. Colavitti et al., "Reactive Oxygen Species as Downstream Mediators of Angiogenic Signaling by Vascular Endothelial Growth Factor Receptor-2/KDR, The Journal of Biological Chemistry, 2002 by The American Society for Biochemistry and Molecular Biology, Inc., Vol. 277, No. 2, Issue of Feb. 1, 3101-3108.					
EXAMINER			DATE CONSIDERED				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.